| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC0272 |
| Trial ID | NCT02588456 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia |
| Year | 2015 |
| Country | United States |
| Company sponsor | University of Pennsylvania |
| Other ID(s) | UPCC 31415, 822967 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||